PIK3CA mutations can initiate pancreatic tumorigenesis and are targetable with PI3K inhibitors
Susan N. Payne(University of Wisconsin Carbone Cancer Center), Dustin A. Deming(University of Wisconsin–Madison)
Cited by 75
Related Papers
ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal–Anal Task Forces whitepaper
|Nature Reviews Clinical Oncology|2020|365
Abstract CT028: A first-in-human phase 1 study of LY3537982, a highly selective and potent KRAS G12C inhibitor in patients with KRAS G12C-mutant advanced solid tumors
|Cancer Research|2023|37
Colon Cancer Tumorigenesis Initiated by the H1047R Mutant PI3K
|PLoS ONE|2016|22